These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9582607)

  • 1. Serum CA 15.3, CEA and ESR patterns in breast cancer.
    Rubach M; Szymendera JJ; Kamińska J; Kowalska M
    Int J Biol Markers; 1997; 12(4):168-73. PubMed ID: 9582607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
    Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
    Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
    Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
    Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
    Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
    Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
    Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
    Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
    Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
    Nicolini A; Carpi A; Ferrari P; Anselmi L
    Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
    Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
    Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers and prognosis in locally advanced breast cancer.
    Martínez-Trufero J; de Lobera AR; Lao J; Puértolas T; Artal-Cortés A; Zorrilla M; Alonso V; Pazo R; Valero MI; Ríos-Mitchell MJ; Calderero V; Herrero A; Antón A
    Tumori; 2005; 91(6):522-30. PubMed ID: 16457152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Ann Oncol; 2013 May; 24(5):1225-31. PubMed ID: 23230137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
    Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study.
    Kurebayashi J; Yamamoto Y; Tanaka K; Kohno N; Kurosumi M; Moriya T; Nishimura R; Ogawa Y; Taguchi T;
    Breast Cancer; 2003; 10(1):38-44. PubMed ID: 12525762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
    Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
    Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
    Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma.
    Grankvist K; Ljungberg B; Rasmuson T
    Int J Cancer; 1997 Apr; 74(2):233-6. PubMed ID: 9133462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.